Lidds Q2: Building value in the pipeline - Redeye

Redeye maintains a positive view on LIDDS after today's Q2 report. The company is building value in its portfolio and is supported by a strong global trend that will bring cancer treatment to the top of the healthcare priority list in the coming years, in our view.

Länk till analysen i sin helhet: https://www.redeye.se/research/819595/lidds-q2-building-value-in-the-pipeline?utm_source=finwire&utm_medium=RSS